Cannabinoid-induced changes in respiration of brain mitochondria

Toxicol Lett. 2014 Nov 18;231(1):62-71. doi: 10.1016/j.toxlet.2014.09.002. Epub 2014 Sep 6.

Abstract

Cannabinoids exert various biological effects that are either receptor-mediated or independent of receptor signaling. Mitochondrial effects of cannabinoids were interpreted either as non-receptor-mediated alteration of mitochondrial membranes, or as indirect consequences of activation of plasma membrane type 1 cannabinoid receptors (CB1). Recently, CB1 receptors were confirmed to be localized to the membranes of neuronal mitochondria, where their activation directly regulates respiration and energy production. Here, we performed in-depth analysis of cannabinoid-induced changes of mitochondrial respiration using both an antagonist/inverse agonist of CB1 receptors, AM251 and the cannabinoid receptor agonists, Δ(9)-tetrahydrocannabinol (THC), cannabidiol, anandamide, and WIN 55,212-2. Relationships were determined between cannabinoid concentration and respiratory rate driven by substrates of complex I, II or IV in pig brain mitochondria. Either full or partial inhibition of respiratory rate was found for the tested drugs, with an IC50 in the micromolar range, which verified the significant role of non-receptor-mediated mechanism in inhibiting mitochondrial respiration. Effect of stepwise application of THC and AM251 evidenced protective role of AM251 and corroborated the participation of CB1 receptor activation in the inhibition of mitochondrial respiration. We proposed a model, which includes both receptor- and non-receptor-mediated mechanisms of cannabinoid action on mitochondrial respiration. This model explains both the inhibitory effect of cannabinoids and the protective effect of the CB1 receptor inverse agonist.

Keywords: AM251; Anandamide; Cannabidiol; Respiratory rate; WIN 55,212-2; Δ(9)-Tetrahydrocannabinol.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arachidonic Acids / pharmacology
  • Benzoxazines / pharmacology
  • Brain / drug effects*
  • Brain / metabolism
  • Cannabidiol / pharmacology
  • Cannabinoid Receptor Agonists / pharmacology*
  • Cannabinoids / pharmacology*
  • Cell Respiration / drug effects
  • Dose-Response Relationship, Drug
  • Dronabinol / pharmacology
  • Drug Inverse Agonism
  • Endocannabinoids / pharmacology
  • Energy Metabolism / drug effects*
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • Morpholines / pharmacology
  • Naphthalenes / pharmacology
  • Piperidines / pharmacology
  • Polyunsaturated Alkamides / pharmacology
  • Pyrazoles / pharmacology
  • Receptor, Cannabinoid, CB1 / drug effects*
  • Receptor, Cannabinoid, CB1 / metabolism
  • Signal Transduction / drug effects
  • Swine

Substances

  • Arachidonic Acids
  • Benzoxazines
  • Cannabinoid Receptor Agonists
  • Cannabinoids
  • Endocannabinoids
  • Morpholines
  • Naphthalenes
  • Piperidines
  • Polyunsaturated Alkamides
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Cannabidiol
  • AM 251
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Dronabinol
  • anandamide